|
Scancell Holdings PLC - Oxford-based pharmaceutical company focused on cancer immunotherapies - Appoints ‘highly experienced senior healthcare executive and entrepreneur’ David Schilansky, effective immediately, as a financial advisor. Says he will also become interim chief financial officer ‘later in April’. Adds that it has launched a global recruitment process for a permanent successor to current CFO Sath Nirmalananthan, who is leaving Scancell and stepping down from the board with effect from April 24, ‘to pursue other professional opportunities.’ Scancell says Schilansky is currently concluding his role as chief executive officer of Ariceum Therapeutics, and starting as a venture partner and entrepreneur-in-residence at Redmile Group. ‘David brings broad and strategic financing expertise to Scancell and will be a strong interim CFO, ensuring continuity and progress in our strategy,’ comments Scancell CEO Phil L’Huillier. ‘We remain laser focused on delivering iSCIB1+ to patients and building shareholder value. Having David in place enables us to seamlessly advance our constructive financing and partnering discussions on our lead ImmunoBody iSCIB1+, now with the recently obtained strong regulatory feedback in hand. Further, David brings valuable investor engagement and strategic financing expertise, including Nasdaq listing experience that will help guide the company as we explore a potential listing in the US.’ Current stock price: 11.48 pence, up 2.0% on Thursday afternoon in London 12-month change: up 41% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
